多重单层LymeSeek检测提升早期莱姆病诊断灰区敏感性
本研究开发了基于微珠的多重流式免疫检测LymeSeek,单次检测同时识别IgM和IgG抗体与8种伯氏疏螺旋体抗原的结合,将荧光信号转化为疾病概率和单一检测结果。该检测在所有疾病阶段总敏感性超过90%且不损失特异性,在盲法样本中能正确区分血清学阳性病例与疾病及非疾病对照,并识别出当前标准双层血清学检测阴性的早期莱姆病病例(伴或不伴游走性红斑)。
要点
- LymeSeek单层多重免疫检测总敏感性超过90%,特异性无损失。
- 可识别标准双层血清学检测阴性的早期莱姆病病例。
- 在盲法样本中正确区分血清学阳性病例与对照。
核心结论
- LymeSeek单层多重免疫检测在所有疾病阶段总敏感性超过90%且不损失特异性,有望提高早期莱姆病诊断准确性。
研究设计与样本
- 开发基于微珠的多重流式免疫检测LymeSeek,单次检测IgM和IgG抗体与8种伯氏疏螺旋体抗原的结合,荧光信号转化为疾病概率和单一检测结果。
- 使用盲法样本评估检测性能,区分血清学阳性病例与疾病及非疾病对照。
主要发现
- 所有疾病阶段总检测敏感性超过90%,无特异性损失。
- 在盲法样本中正确区分血清学阳性病例与疾病及非疾病对照。
- 识别出当前标准双层血清学检测阴性的早期莱姆病病例,包括伴或不伴游走性红斑者。
关键数值与推荐
- 检测8种伯氏疏螺旋体抗原对应的16种诊断抗体。
- 总敏感性超过90%。
- 特异性高到足以消除第二层检测的需要。
临床怎么用
- LymeSeek作为单层检测可提高早期莱姆病诊断准确性,尤其适用于诊断灰区期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lyme disease, caused by the spirochete Borrelia burgdorferi, is the most common vector-borne disease in the U.S. and a growing public health concern due to the clinically challenging nature of the disease. Prompt antibiotic treatment early in the infection results in the best patient outcomes, while delayed treatment increases the risk of developing debilitating chronic symptoms. Because standard-of-care diagnostic tests (standardized and modified two-tier tests) have low sensitivity during the first few weeks of infection, current recommendations for diagnosing early Lyme disease rely heavily on observation and recognition of erythema migrans (EM). However, a significant proportion of Lyme disease patients develop an atypical-appearing rash, or no rash is observed. To improve diagnostic accuracy, we developed LymeSeek, a microbead-based multiplex flow immunoassay performed as a single test that detects binding of IgM and IgG antibodies to a novel combination of eight B. burgdorferi antigens. Fluorescent signals from bound antibodies are translated into a disease probability and a single test result-either detected or not detected. Overall test sensitivity across all disease stages was over 90%, with no loss of specificity. The LymeSeek test performed well in blinded panels, correctly differentiating serologically positive cases from both disease and non-disease controls. The test also identified early Lyme disease cases, with and without an observed EM rash, that were negative on the current standard-of-care two-tier serological tests. The LymeSeek test has the potential to increase diagnostic accuracy and improve patient outcomes, particularly during the diagnostic gray zone of early Lyme disease.IMPORTANCEStandard and modified two-tier serological tests for Lyme disease are not sensitive enough to diagnose patients within the first few weeks of infection, when antibiotic treatment is recognized as being most effective. This report describes a single-tier multiplex immunoassay that utilizes detection of 16 diagnostic antibodies against eight Borrelia antigens and interpretation by a machine learning-developed algorithm that demonstrates sensitivity high enough to accurately diagnose over 90% of Lyme disease cases, including those in the early diagnostic gray zone period when diagnostic uncertainty is highest. Specificity is high enough to eliminate the need for a second-tier test.
引用
- Ahern H, Kirk J, Stafford P, et al. Multiplex single-tier LymeSeek test improves sensitivity during the diagnostic gray zone of early Lyme disease. J Clin Microbiol. 2026. PMID: 42831617. doi:10.1128/jcm.00879-26
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。